Jackson Hole Capital Partners LLC Purchases 19,750 Shares of Enhabit, Inc. (NYSE:EHAB)

Jackson Hole Capital Partners LLC raised its position in shares of Enhabit, Inc. (NYSE:EHAB) by 23.5% in the 4th quarter, Holdings Channel.com reports. The firm owned 103,765 shares of the company’s stock after acquiring an additional 19,750 shares during the quarter. Jackson Hole Capital Partners LLC’s holdings in Enhabit were worth $1,074,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently made changes to their positions in EHAB. Brooks Moore & Associates Inc. raised its position in Enhabit by 5.1% during the third quarter. Brooks Moore & Associates Inc. now owns 26,950 shares of the company’s stock valued at $303,000 after purchasing an additional 1,300 shares in the last quarter. Rhumbline Advisers raised its position in Enhabit by 2.3% during the third quarter. Rhumbline Advisers now owns 162,845 shares of the company’s stock valued at $1,832,000 after purchasing an additional 3,631 shares in the last quarter. Orion Portfolio Solutions LLC raised its position in Enhabit by 5.3% during the third quarter. Orion Portfolio Solutions LLC now owns 75,608 shares of the company’s stock valued at $851,000 after purchasing an additional 3,795 shares in the last quarter. Oppenheimer & Co. Inc. raised its position in Enhabit by 20.5% during the third quarter. Oppenheimer & Co. Inc. now owns 35,324 shares of the company’s stock valued at $397,000 after purchasing an additional 6,000 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new stake in Enhabit during the third quarter valued at about $73,000.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on EHAB. UBS Group upgraded Enhabit from a “sell” rating to a “neutral” rating and set a $9.50 price objective on the stock in a report on Thursday, March 7th. Oppenheimer reissued a “market perform” rating on shares of Enhabit in a research note on Thursday, March 7th. Finally, Jefferies Financial Group cut their target price on Enhabit from $15.00 to $14.00 and set a “buy” rating on the stock in a research note on Wednesday, March 6th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $12.08.

Enhabit Stock Down 2.9 %

Enhabit stock traded down $0.29 during trading hours on Thursday, hitting $9.88. 278,357 shares of the stock traded hands, compared to its average volume of 569,422. The firm’s 50-day moving average price is $10.27 and its two-hundred day moving average price is $9.89. The company has a current ratio of 1.53, a quick ratio of 1.53 and a debt-to-equity ratio of 0.76. The company has a market cap of $495.33 million, a PE ratio of -6.28, a PEG ratio of 1.57 and a beta of 1.96. Enhabit, Inc. has a one year low of $7.12 and a one year high of $14.59.

Enhabit (NYSE:EHAB) last released its earnings results on Wednesday, March 6th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.01. Enhabit had a negative net margin of 7.69% and a positive return on equity of 1.55%. The firm had revenue of $260.60 million during the quarter, compared to analyst estimates of $260.30 million. During the same period last year, the business earned $0.32 earnings per share. On average, research analysts forecast that Enhabit, Inc. will post 0.24 EPS for the current year.

About Enhabit

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.